Home Featured Page 13

Featured

Latest

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

Psilocybin for Chronic Suicidal Ideation: Scott T. Aaronson on Safety, an Efficacy Signal, and the Role of Expectations

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the...

Logan Davidson – American Ibogaine, State Strategy, and the Future of...

Areyto Boriken – Ethnobotanical Adventure

The Ram Dass Institute of Psychedelic Studies with The Dying Inaugural...

International Conference on Assisted Dying and Other End of Life Care...

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

EDITOR PICKS

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

“If I can’t change my views based on evidence, then why...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.